PARIS — In this exclusive interview from the International Liver Congress 2018, Mani Subramanian, PhD, provides an update on Gilead’s ongoing clinical trials for the treatment of advanced fibrosis in patients with nonalcoholic steatohepatitis.
“We know that NASH is a problem that’s being increasingly appreciated,” Subramanian, senior vice president of liver disease therapeutics at Gilead, told Healio Gastroenterology and Liver Disease. “In the coming decade it’s going to become probably the leading cause of complications due to end-stage liver disease, including liver failure, death, and the need for liver transplantation.”
During the meeting, Gilead presented new data on the acetyl-CoA carboxylase (ACC) inhibitor GS-0976; the selective, nonsteroidal Farnesoid X receptor (FXR) agonist GS-9674; and an apoptosis-signal regulating kinase (ASK1) inhibitor — known as selonsertib — in combination with either GS-0976 or GS-9674, for the treatment of advanced fibrosis in NASH.
“At Gilead, we have a commitment and effort in two broad areas,” Subramanian said. “One is, how can we reduce liver fibrosis in these patients who have advanced fibrosis such as F3 or F4 due to NASH? And the other area ... is our efforts to help in the diagnosis of these patients using noninvasive tests that will obviate the need for liver biopsy, which is both invasive and definitely is quite restrictive in terms of broader access.”
For more information:
Lawitz E, et al. PS-105. Presented at: International Liver Congress; Apr. 11-15, 2018; Paris, France.
Mantry P, et al. FRI-488. Presented at: International Liver Congress; Apr. 11-15, 2018; Paris, France.
Schwabi P, et al. FRI-248. Presented at: International Liver Congress; Apr. 11-15, 2018; Paris, France.
Disclosure: Subramanian is an employee of Gilead.